IPO Timeline Raw facts
Company Overview
| Stock Name | Ab&b Bio-Tech-B |
|---|---|
| Stock Code | 02627 |
| Company Full Name | Ab&B Bio-Tech Co., Ltd. |
| Industry | Biotech & Pharma |
| Principal Activities | industry veteran with over 15 years of experience in the biotechnology and pharmaceutical industries |
| Listing Date | 2025-08-11 |
| Listing Rules Era | New Rules (after Aug 2025) |
| Listing Rules Chapter | Chapter 18A |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國 江蘇省泰州市 醫藥高新區 杏林路32號 |
| Business Address (Hong Kong) | 248 Queen’s Road East Wanchai Hong Kong |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.abbbio.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism B |
|---|---|
| Offer Price | HK$ 12.90 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 2,580 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2025-07-31 to 2025-08-05 |
| Global Offering Shares | 33,442,600 shares |
| HK Public Offer Shares (Initial) | 3,344,260 shares (10.0%) |
| Public Offer Lots (Initial) | 16,721lots (Pool A8,360lots,Pool B8,361lots) |
| International Placing Shares (Initial) | 30,098,340 shares (90.0%) |
| Offer Ratio | ~8.5% |
| Total Shares Post-IPO | 393,442,600 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | 中信证券(香港)有限公司 CE AAK249 |
| Cornerstone Share | 21.3% |
| Clawback Tiers | Mechanism B: no clawback |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 431,409,540 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 2,580 |
| 2 lots | 400 | HK$ 5,160 |
| 3 lots | 600 | HK$ 7,740 |
| 4 lots | 800 | HK$ 10,320 |
| 5 lots | 1,000 | HK$ 12,900 |
| 6 lots | 1,200 | HK$ 15,480 |
| 7 lots | 1,400 | HK$ 18,060 |
| 8 lots | 1,600 | HK$ 20,640 |
| 9 lots | 1,800 | HK$ 23,220 |
| 10 lots | 2,000 | HK$ 25,800 |
| 15 lots | 3,000 | HK$ 38,700 |
| 20 lots | 4,000 | HK$ 51,600 |
| 25 lots | 5,000 | HK$ 64,500 |
| 30 lots | 6,000 | HK$ 77,400 |
| 35 lots | 7,000 | HK$ 90,300 |
| 40 lots | 8,000 | HK$ 103,200 |
| 45 lots | 9,000 | HK$ 116,100 |
| 50 lots | 10,000 | HK$ 129,000 |
| 100 lots | 20,000 | HK$ 258,000 |
| 150 lots | 30,000 | HK$ 387,000 |
| 200 lots | 40,000 | HK$ 516,000 |
| 250 lots | 50,000 | HK$ 645,000 |
| 300 lots | 60,000 | HK$ 774,000 |
| 350 lots | 70,000 | HK$ 903,000 |
| 400 lots | 80,000 | HK$ 1,032,000 |
| 450 lots | 90,000 | HK$ 1,161,000 |
| 500 lots | 100,000 | HK$ 1,290,000 |
| 1,000 lots | 200,000 | HK$ 2,580,000 |
| 1,500 lots | 300,000 | HK$ 3,870,000 |
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,000 lots | 400,000 | HK$ 5,160,000 |
| 2,500 lots | 500,000 | HK$ 6,450,000 |
| 3,000 lots | 600,000 | HK$ 7,740,000 |
| 3,500 lots | 700,000 | HK$ 9,030,000 |
| 4,000 lots | 800,000 | HK$ 10,320,000 |
| 4,500 lots | 900,000 | HK$ 11,610,000 |
| 5,000 lots | 1,000,000 | HK$ 12,900,000 |
| 6,000 lots | 1,200,000 | HK$ 15,480,000 |
| 7,000 lots | 1,400,000 | HK$ 18,060,000 |
| 8,361 lots | 1,672,200 | HK$ 21,571,380 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 9.95B |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap met, expected inclusion ~2027-03-08 |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 5,075,409,540 |
|---|---|
| H-Share Market Cap (at Offer Price) | HK$ 3,823,067,800 |
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not applicable (loss-making) |
| Profit/Loss Status | Net loss RMB 258.7 million |
| Period-End Cash Balance | RMB 132.19 million |
| Listing Expenses | ~HK$ 54,400,000 |
| Listing Expenses / Funds Raised | ~11.5% |
| Total Pre-IPO Investment | RMB 994.38 million |
| First Day Close | HK$ 33.28 |
|---|---|
| First Day Open | HK$ 33.0 |
| First Day Change | 157.98% |
| First Day Volume | 8992780.0 |
| First Day Turnover | 297614000.0 |
| Use of Proceeds | 1、約63.6%或266.9百萬港元將分配至核心產品的開發及國內外注冊;
2、約18.1%或76.4百萬港元將用于其他在研疫苗的開發和注冊;
3、約8.4%或35.4百萬港元將分配至提升生產及商業化能力;
4、約4.9%或20.8百萬港元將分配至技術平臺的開發、升級及運營;
5、約5.0%或21.0百萬港元將分配至營運資金及其他一般公司用途。 |
Underwriting Syndicate
Service Providers
| Role | Institution |
|---|---|
| Legal Advisor to Company |
年利达律师行 北京国枫律师事务所 北京市嘉源律师事务所 |
| Legal Advisor to Sponsors/Underwriters |
高伟绅律师行 通商律师事务所 |
| Auditor and Reporting Accountant | 德勤•关黄陈方会计师行 |
| Industry Advisor | 弗若斯特沙利文(北京)咨询有限公司上海分公司 |
| Receiving Banks | 中国银行(香港)有限公司 |
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 嘉兴鑫扬及华泰资本投资(与华泰背对背总回报掉期及华泰客户总回报掉期有关) | 13,000,000 USD | 7,113,600 | 21.30% | 1.80% | 6 months | 2026-02-11 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Mr. An Youcai | Mr. An Youcai |
| Company Secretary | Ms. Zhang Yangyang | Ms. Zhang Yangyang |
| Executive Director | 安有才 | An Youcai |
| Non-Executive Director | 程千文 | Cheng Qianwen |
| Independent Non-Executive Director | 李向明 | Li Xiangming |
| Executive Director | 李润香 | Li Runxiang |
| Non-Executive Director | 于建林 | Yu Jianlin |
| Independent Non-Executive Director | 李晓青 | Li Xiaoqing |
| Executive Director | 何一鸣 | He Yiming |
| Non-Executive Director | 杜沐 | Du Mu |
| Independent Non-Executive Director | 陈乘贝 | Chen Chengbei |
| Independent Non-Executive Director | 封浩 | Feng Hao |
| Independent Non-Executive Director | 王曙光 | Wang Shuguang |
| Independent Non-Executive Director | 王威 | Wang Wei |
Major Shareholders
| Major Shareholders & Holdings | The Controlling Shareholder Group comprises the Persons Acting in Concert Group (Mr. An, 江蘇糶宇 and Mr. He) and the Employee Shareholding Platforms (泰州慧達, 泰州慧融, 泰州慧隆, 泰州慧新, 泰州慧寧 and 泰州慧嘉), which collectively hold approximately 45.55% of the Shares. Immediately after the completion of the Global Offering, the Controlling Shareholder Group will collectively hold approximately 41.68% of the Shares (assuming the Over-Allotment Option is not exercised). |
|---|
Market Sentiment
With an offer price of HK$12.9 and an entry threshold of HK$2,580, the IPO drew an extraordinary oversubscription ratio of 4,007.64 times, signaling intense retail demand for this 18A biotech listing. The overall hit rate was a mere 9.87%, meaning only about one in ten applications succeeded, highlighting the fierce competition. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
The tier distribution shows a stark inefficiency at the boundary: 甲尾 applicants, applying for 300,000 shares, could expect just 0.24 lots, while 乙头 subscribers with 400,000 shares saw an expected 0.6 lots—more than double the lots for only a 33% increase in shares. This indicates a disproportionately large jump in allocation probability when crossing into the B tier. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Successful applicants were predominantly male (61.3%) with an average age of 42.8, and a striking 69.7% hailed from mainland China, underscoring the strong cross-border demand for Hong Kong biotech IPOs. Hong Kong residents accounted for just 29.5% of the allotment, pointing to a heavily mainland-driven investor base. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)




